Clinical trial

Pancreatic Polypeptide as a Modulator of Amylin- Induced Satiety in Healthy Humans

NCT07506369

Drugs and interventions used in this trial

3 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Unmapped registry intervention Amylin (Pramlintide) Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention Pancreatic Polypeptide (PP) Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention Placebo (NaCl 0.9 % solution) Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

Pancreatic Polypeptide as a Modulator of Amylin- Induced Satiety in Healthy Humans

Design: INTERVENTIONAL · Status: RECRUITING · Phase: NA

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusRECRUITING

Study typeINTERVENTIONAL

Start date2026-04-01

PhaseNA

Conditions

Obesity & Overweightunresolved

Interventions

Amylin (Pramlintide)DRUG

Pancreatic Polypeptide (PP)DRUG

Placebo (NaCl 0.9 % solution)DRUG

Sponsors & collaborators

University Hospital, Gentofte, Copenhagenlead sponsor

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT07506369 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.